NCT03432741 2025-05-26
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Mayo Clinic
Phase 1 Terminated
Mayo Clinic
Thomas Jefferson University
Eastern Cooperative Oncology Group
National Institutes of Health Clinical Center (CC)
Celgene
SWOG Cancer Research Network